阿达木单抗高谷浓度类风湿关节炎患者延长给药间隔的非劣效随机试验
这项开放标签非劣效随机试验纳入阿达木单抗谷浓度>8 µg/mL的类风湿关节炎患者,随机分为每3周给药一次或维持每2周一次。28周后延长间隔组ΔDAS28-ESR为-0.14±0.61,继续组为0.30±0.52,组间均值差0.44(95%CI 0.12至0.76,p=0.01),支持延长给药间隔不劣于继续标准给药。
要点
- 阿达木单抗谷浓度>8 µg/mL的RA患者可将给药间隔延长至每3周一次。
- 28周ΔDAS28-ESR组间均值差0.44(95%CI 0.12至0.76,p=0.01),支持延长间隔。
- 延长给药间隔未导致疾病控制丧失,非劣效界值为0.6分。
核心结论
- 阿达木单抗谷浓度>8 µg/mL的RA患者将标准给药间隔延长至每3周一次,28周内未丧失疾病控制。
主要发现
- 延长间隔组28周ΔDAS28-ESR为-0.14±0.61,继续标准间隔组为0.30±0.52。
- 组间均值差0.44(95%CI 0.12至0.76,p=0.01),显著有利于延长间隔组。
关键数值与推荐
- 入组条件为阿达木单抗40 mg每2周一次治疗至少28周且谷浓度>8 µg/mL。
- 主要终点为28周ΔDAS28-ESR,非劣效界值为0.6分。
临床怎么用
- 对阿达木单抗谷浓度>8 µg/mL的RA患者,可考虑将给药间隔延长至每3周一次以降低过度暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High adalimumab serum concentrations do not result in better response in patients with rheumatoid arthritis (RA), suggesting overexposure. We investigated whether patients with adalimumab concentrations >8 µg/mL can prolong their dosing interval by 50% without a clinically relevant change in disease activity. METHODS: Consecutive patients with RA, treated with adalimumab 40 mg every other week for at least 28 weeks, were approached for this randomised, open-label, non-inferiority trial. Patients with adalimumab trough concentrations >8 µg/mL were randomly (1:1) assigned to dose-interval prolongation of once every 3 weeks or continuation of every other week. Primary outcome was the change in disease activity score of 28 joints (ΔDAS28-ESR) after 28 weeks, with a non-inferiority margin of 0.6 points. RESULTS: In total, 147 patients were screened. Fifty-five patients had concentrations >8 µg/mL and were randomised. Mean ΔDAS28 after 28 weeks was -0.14±SD 0.61 in the prolongation group and 0.30±0.52 in the continuation group. Mean difference was significantly in favour of the prolongation group: 0.44 (95% CI 0.12 to 0.76, p=0.01). CONCLUSIONS: Adalimumab-treated patients with RA with trough concentrations >8 µg/mL can prolong their standard dosing interval to once every 3 weeks without loss of disease control. TRIAL REGISTRATION NUMBER: NTR3509; Results.
引用
- l'Ami MJ, Krieckaert CL, Nurmohamed MT, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2017. PMID: 28939629. doi:10.1136/annrheumdis-2017-211781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。